
Biogen to Acquire Human Immunology Biosciences in $1.8 Bln Deal
Biotechnology Company Biogen, on Wednesday, announced an agreement to acquire Human Immunology Biosciences (HI-Bio) for $1.15 billion upfront and up to $650 million in potential milestone payments, boosting Biogen’s pipeline with targeted therapies for severe immune-mediated diseases. HI-Bio’s lead asset, Felzartamab, is a fully human anti-CD38 monoclonal antibody. Felzartamab depletes CD38+ cells, including plasma and […]











